# Narcolepsia tipo 2

> Página oficial: https://raras.org/doenca/narcolepsia-tipo-2
> Fonte: Raras.org — Banco de Dados de Doenças Raras em Português (CC BY-NC-SA 4.0)
> Última atualização: 2026-05-07

## Identificadores

- **ORPHA**: 83465 — https://www.orpha.net/en/disease/detail/83465
- **CID-10**: G47.4
- **OMIM**: none — https://omim.org/entry/none

## Descrição clínica

A narcolepsia sem cataplexia é caracterizada por sonolência excessiva durante o dia associada a vontade incontrolável de dormir e por vezes paralisia no sono, alucinações hipnagógicas e comportamento automático.

## Epidemiologia e herança

- **Prevalência**: Unknown
- **Padrão de herança**: Unknown

## Sinais e sintomas (5 fenótipos HPO)

- **Insônia** — HPO: HP:0100785 (Muito frequente (99-80%))
- **Anormalidade do sono** — HPO: HP:0002360 (Muito frequente (99-80%))
- **Sonolência diurna excessiva** — HPO: HP:0001262 (Muito frequente (99-80%))
- **Alucinações** — HPO: HP:0000738 (Muito frequente (99-80%))
- **Comportamento atípico** — HPO: HP:0000708 (Ocasional (29-5%))

## Genes associados (4)

- **HLA-DRB1** — HLA class II histocompatibility antigen, DRB1 beta chain [Major susceptibility factor in]
  - Função: A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting c
- **HLA-DQB1** — HLA class II histocompatibility antigen, DQ beta 1 chain [Major susceptibility factor in]
  - Função: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cle
- **HCRT** — Hypocretin neuropeptide precursor [Candidate gene tested in]
  - Função: Neuropeptides that play a significant role in the regulation of food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary home
- **ZNF365** — Talanin [Major susceptibility factor in]
  - Função: May play a role in uric acid excretion

## Ensaios clínicos ativos (8)

- **NCT07502443** [RECRUITING]: A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 — https://clinicaltrials.gov/study/NCT07502443
- **NCT07096674** [RECRUITING]: A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — https://clinicaltrials.gov/study/NCT07096674
- **NCT07299097** [RECRUITING]: Epidemiology of Narcolepsy Type 1 and Type 2 in Spain — https://clinicaltrials.gov/study/NCT07299097
- **NCT06767683** [RECRUITING]: A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia — https://clinicaltrials.gov/study/NCT06767683
- **NCT06952699** [RECRUITING]: A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) — https://clinicaltrials.gov/study/NCT06952699
- **NCT06752668** [RECRUITING]: A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia — https://clinicaltrials.gov/study/NCT06752668
- **NCT07006233** [RECRUITING]: A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia — https://clinicaltrials.gov/study/NCT07006233
- **NCT07493265** [NOT_YET_RECRUITING]: A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy — https://clinicaltrials.gov/study/NCT07493265
- **NCT06251063** [COMPLETED]: Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence — https://clinicaltrials.gov/study/NCT06251063
- **NCT06555783** [COMPLETED]: A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 — https://clinicaltrials.gov/study/NCT06555783

## Doenças relacionadas (por similaridade fenotípica)

- [Narcolepsia](https://raras.org/doenca/narcolepsia) — ORPHA:619284 — 5 sintomas em comum
- [Tripanossomíase Africana](https://raras.org/doenca/tripanossomiase-africana) — ORPHA:3385 — 5 sintomas em comum
- [Doença de Huntington](https://raras.org/doenca/doenca-de-huntington) — ORPHA:399 — 4 sintomas em comum
- [Porfiria hepática](https://raras.org/doenca/porfiria-hepatica) — ORPHA:659694 — 4 sintomas em comum
- [Encefalite infecciosa](https://raras.org/doenca/encefalite-infecciosa) — ORPHA:98252 — 4 sintomas em comum
- [NÃO RARA NA EUROPA: Doença de Parkinson](https://raras.org/doenca/nao-rara-na-europa-doenca-de-parkinson) — ORPHA:319705 — 3 sintomas em comum
- [Doença de Creutzfeldt-Jakob hereditária](https://raras.org/doenca/doenca-de-creutzfeldt-jakob-hereditaria) — ORPHA:282166 — 3 sintomas em comum
- [Citrulinemia, tipo II](https://raras.org/doenca/citrulinemia-tipo-ii) — ORPHA:247585 — 3 sintomas em comum
- [Gangliosidose GM2](https://raras.org/doenca/gangliosidose-gm2) — ORPHA:309152 — 3 sintomas em comum
- [Encefalite receptor NMDA](https://raras.org/doenca/encefalite-receptor-nmda) — ORPHA:217253 — 3 sintomas em comum

## Importante

O Raras **não diagnostica e não prescreve**. Esta página é educativa e informativa.
Pacientes devem consultar profissionais de saúde qualificados para decisões clínicas.

---

**Citação sugerida**: Raras.org — Narcolepsia tipo 2. Disponível em: https://raras.org/doenca/narcolepsia-tipo-2
**Formato HTML**: https://raras.org/doenca/narcolepsia-tipo-2
**Formato RDF/Turtle**: https://raras.org/api/rdf?orpha=83465